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Abstract 
Background: Sushi Domain Containing 2 (SUSD2) has been identified as a regulator of colon and breast cancer. 
Increasing evidence suggests that SUSD2 plays a key role in tumorigenesis. However, the SUSD2 expression status and 
its functions in hepatocellular carcinoma (HCC) are still unrevealed. In the present study, we intended to investigate 
SUSD2 expression status and its correlation with the clinicopathological features in HCC patients. Furthermore,we 
examined the influence of SUSD2 on the proliferation, apoptosis, invasion and migration of the HCC cell lines HepG2 
and SMMC7721.
Methods: We evaluated the SUSD2 expression in HCC tissues and paired normal liver tissues by quantitative real‑
time PCR and western blotting analysis. The clinicopathological significance of SUSD2 was investigated by immuno‑
histochemistry (IHC) on a HCC tissue microarray. Receiver operating characteristic (ROC) analysis was applied to deter‑
mine the optimal cut‑off score for positive expression of SUSD2. The correlation between SUSD2 protein expression 
and clinicopathological features of HCC was analyzed by Chi square test. The cell proliferation, apoptosis, invasion and 
migration potential were observed to detect the functions of SUSD2 in HCC cells.
Results: Decreased expression of SUSD2 mRNA and protein were observed in the majority of HCC tissues, compared 
with paired normal liver tissues. When SUSD2 high expression percentage was determined to be above 52.5 % (area 
under ROC curve = 0.769, P = 0.000), low expression of SUSD2 was observed in 62.2 % (112/180) of HCC tissues and 
high expression of SUSD2 was observed in all normal liver tissues (16/16) by IHC. Decreased expression of SUSD2 
in patients was correlated with high histological grade (χ2 = 5.198, P = 0.023), advanced clinical stage (χ2 = 30.244, 
P = 0.000), pT status (χ2 = 33.175, P = 0.000), pN status (χ2 = 4.785, P = 0.029), pM status (χ2 = 4.620, P = 0.032). 
Down‑regulation of SUSD2 promoted cell proliferation,invasion and migration,reduced the cell apoptosis.
Conclusions: Our findings suggest that SUSD2 may play as a tumor suppressor in HCC cells and could be served as 
an additional potential marker for diagnosis.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignancy worldwide. Population-based studies 
show that the incidence rate continues to approximate 
the death rate, indicating that most of the patients who 
develop HCC die of it [1]. Surgical resection or liver 
transplantation is usually considered curative treatment 
for early HCC [2]. Unfortunately, exceeding 50–70  % 
of HCC patients present with advanced disease that is 
not amenable to surgical resection or transplantation 
and thus the 5-year relative survival rate for patients 
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with HCC is only 7  % [3]. HCC always develops in the 
setting of liver cirrhosis associated with hepatic regen-
eration after tissue damage caused by a chronic hepati-
tis B or C virus infection, chronic alcohol consumption 
or metabolic influences [4]. The mutations occurring in 
single or multiple oncogenes or tumor suppressor genes 
are increasingly recognized as critical determinants of 
carcinogenesis [5]. Molecular analysis of HCC revealed 
genetic and epigenetic alterations that lead to the dereg-
ulation of key proto-oncogenes and tumor suppressor 
genes including P53, β-catenin, ErbB receptor factor, 
p16, E-cadherin, and cyclooxygenase 2 in this cancer [6, 
7]. However, due to lack of early diagnosis methods and 
traditional stratification schemes based on clinical char-
acteristics such as AJCC TNM stage and BCLC stage 
provide limited prognostic guidance in the management 
of HCC patients, the majority of HCC cases were diag-
nosed at terminal stages and the long-term prognosis 
remained unfavorable [8, 9]. Biomarkers that can predict 
clinical outcome of specific cancers are helpful for the 
development of therapeutic strategies in the earlier stages 
of the diseases [10]. Thus, it is prevalent to discovery 
novel biomarkers for accurate diagnosis, prognosis and 
individualized medication of HCC.
SUSD2 (Sushi Domain Containing 2) was first identi-
fied in mouse as a tumor-reversing gene. Sugahara T 
reported that the mouse homolog SUSD2 was down-
regulated in Ki3T3 cells compared with NIH3T3 cells 
and indicated that upregulation of SUSD2 in HT1080 
cells and HeLa cells inhibits clonogenicity, anchorage-
independent growth, migration, and invasion [11, 12]. 
Their work indicated a possible tumor suppressive role 
of mouse SUSD2. Recently, the human SUSD2 has been 
shown is located on chromosome 22 and encodes an 822-
amino acid type I membrane protein containing somato-
medin B, AMOP, von Willebrand factor type D, and Sushi 
domains, which are frequently found in molecules play-
ing important roles in cell–cell and cell–matrix adhesion 
[13]. Currently, SUSD2 has been reported to be dysregu-
lated in some cancers and accumulating evidences sug-
gested that reduced expression of SUSD2 plays a key role 
in tumorigenesis. Pan et al. showed that SUSD2 expres-
sion was downregulated both on mRNA and protein 
levels in most of colon cancer and cell lines. SUSD2 is 
indispensable for the growth inhibitory effect of CSBF/
C10orf99 on colon cancer cells and recombinants 
SUSD2-Fc can block its function [14]. However, Wat-
son et  al. reporteded that SUSD2 was high expression 
in human breast cancer. Their study described that the 
interaction of SUSD2 with Gal1 increased the invasion of 
breast cancer cells and contributed to a potential immune 
evasion mechanism through induction of apoptosis of 
Jurkat T cells [13]. Their results suggested SUSD2 as an 
oncogene in breast cancer. Up to present, the published 
work suggests that the status of SUSD2 expression may 
be an important factor in tumorigenesis, but the function 
in different cancers may be different; furthermore, little 
is known about the effect of SUSD2 expression on HCC 
patients and prognosis.
In this study, we examined the expression pattern of 
SUSD2 in HCC patients, and the correlation between 
its expression levels with clinicopathological variables 
of HCC. We observed a significant low expression level 
of SUSD2 in patients with HCC. Reduced expression of 
SUSD2 was correlated to progressive features in HCC 
patients. Furthermore, we have investigated the mecha-
nism of SUSD2 in HCC cell lines. These results show that 
exogenous overexpression of SUSD2 suppresses the cell 
proliferation, invasion and migration of HCC cells and 
promotes the cell apoptosis in vitro.
Methods
Patients and tissue specimens
In this study, 8 pairs of fresh HCC tissues and adjacent 
nonmalignant liver tissue were collected from patients 
for Western blotting and qRT-PCR analysis between 
2012 and 2014. A total of 180 paraffin-embedded tis-
sues diagnosed with HCC at the Centre for Liver Disease, 
458th Hospital of PLA (Guangzhou, China), between 
January 2002 and December 2013 was retrieved for TMA 
construction and IHC analysis. Of the 180 HCC sam-
ples,16 matched adjacent non-malignant tissues were 
available as controls. None of the patients had received 
preoperative anticancer treatment. All patients in this 
study were classified according to the 2002 TNM (tumor-
node-metastasis) staging of International Union Against 
Cancer and the American Joint Committee on Cancer 
(AJCC). The median age of patients was 42 years (range, 
16–98  years), and 135 (75.0  %) were males, 45 (30.0  %) 
were females, clinicopathological features of patients 
including age at diagnosis, sex, histological grade, clinical 
stage and pTNM status. Written informed consent was 
obtained from all patients for use of the tissue samples 
and clinical records. The study protocol was performed 
under the approval by the Ethic Committee of the 458th 
Hospital of PLA.
Western blot analysis
Total protein was isolated from 8 pairs of fresh HCC tis-
sue and adjacent nonmalignant liver tissue. Equal amount 
of tissue lysates were resolved by SDS-polyacrylamide 
gel electrophoresis (PAGE) and electrotransferred on 
a polyvinylidene difluoride membrane (Millipore). The 
membranes were blocked in 5 % non-fat dry milk diluted 
with TBST (10  mM Tris–HCl and 0.05  % Tween 20) at 
4  °C overnight. The membranes were then incubated 
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with primary antibodies at room temperature for 2  h, 
followed by incubation with appropriate secondary anti-
bodies(1:1000, Santa Cruz Biotechnology, USA) at room 
temperature for 2 h. The primary antibodies were poly-
clonal rabbit anti-human antibody against SUSD2 (1:500 
dilution; Sigma) and monoclonal rabbit anti human 
antibody against β-actin (1:2000 dilution; Cell Signaling 
Technology). The membranes were washed with TBST 
for three times, and the immunoreactive band were visu-
alized using the ECL plus Western blot detection kit.
Quantitative reverse transcription PCR (qRT–PCR)
Total RNA was extracted from eight pairs of fresh HCC 
tissue and adjacent nonmalignant liver tissue using 
RNAiso Plus reagent (Takara, Dalian, China). Quali-
fied total RNAs were reversely transcribed into first-
strand cDNAs by using the PrimeScript® RT reagent Kit 
(Takara, Dalian, China). For the SUSD2 gene, the forward 
primer was 5′-CTCCAATGACTGCCGCAACTA-3′, and 
the reverse primer was 5′-GAACATCCTTTCAGGTCC 
ATCC-3′. For the β-actin gene,the forward primer was 
5′-CTCCAATGACTGCCGCAACTA-3, and the reverse 
primer was 5′-GAACATTCCTTTCAGGTCCATCC-3′. 
Realtime PCR was carried out using an ABI 7500 real-
time PCR amplifier (Applied Biosystems, USA) to deter-
mine the expression pattern of SUSD2 mRNA in each of 
the HCC sample as well as the paired adjacent non-can-
cerous tissue. Quantitative real-time PCR was performed 
by using the SYBR® Premix Ex TaqTM II Kit (Takara, 
China)in a total volume of 20  μl. The PCR conditions 
were as follows: 95 °C for 30 s, 40 cycles of amplification 
at 95 °C for 5 s and 60 °C for 34 s, followed by additional 
dissociation stage for testing reaction specificitywas per-
formed to generate a melting curve for confirmation of 
amplification specificity. β-actin was used as the refer-
ence gene. The relative levels of gene expression were 
represented as ΔCt  =  Ct(gene)−Ct(reference), and the fold 
change of gene expression was calculated by the 2−ΔΔCt 
method. Experiments were repeated in triplicate.
Construction of tissue microarrays (TMA) 
And immunohistochemistry
Tissue microarray was constructed in accordance with 
previously described methods [15]. In brief, the slides 
were reviewed by a pathologist to determine and mark 
out representative tumor areas. Duplicates of 0.6-mm 
diameter cylinders were punched from representa-
tive areas of individual donor tissue block, and then re-
embedded into a recipient paraffin block in a defined 
position, using a tissue arraying instrument (Beecher 
Instruments, Silver Spring, MD). In our constructed 
liver tissue-TMA, three cores of a sample were selected 
from each primary HCC and normal liver tissue. Then, 
for the need of immunohistochemistry analysis, TMA 
block would be cut into several 5-μm sections. The TMA 
block contained 180 HCC and 16 specimens of normal 
liver tissues. For immunohistochemistry, the TMA slides 
were dried overnight at 37  °C, deparaffinized, rehy-
drated. Endogenous peroxidase activity was blocked 
with 0.3  % hydrogen peroxide for 20  min. For antigen 
retrieval, slides were heated in a microwave oven for 
10 min in 10 mmol/L citrate buffer, pH 6.0. After block-
ing with 5 % normal goat serum at room temperature for 
30 min, the slides were then incubated with SUSD2 pri-
mary antibody (Rabbit polyclonal, Sigma) at a dilution 
of 1:100 at 4  °C overnight and subsequently incubated 
with polymer peroxidase-labeled secondary antibody 
(Zhongshan biotech, China) at a concentration of 1:100 
for 30 min at 37 °C. The final detection was visualized by 
using DAB Horseradish Peroxidase Color Development 
Kit (Beyotime, China) after hematoxylin counterstain-
ing. The phosphate-buffered saline was set as negative 
control.
Evaluation of immunohistochemistry results and selection 
of cut‑off scores
Immunoreactivity for SUSD2 protein was scored by 
semi-quantitative method by evaluating the number 
of positive tumor cells over the total number of tumor 
cells. Scores were assigned by using 5  % increments (0, 
5, 10… 100 %). SUSD2 expression was assessed by three 
independent pathologists (Cuixia.C, R.S and J.Z) who 
were blinded to clinicopathologic data. Their conclu-
sions were in complete agreement in approximately 85 % 
of the cases, which identified this scoring method was 
highly reproducible. If two or all of them were consist-
ent with the results they reported, the value was selected. 
If the results were completely different, all three worked 
together to confirm the score.
Receiver–operator curve (ROC) analysis was applied to 
determine cut-off scores for tumor ‘‘high expression’’ by 
using the 0, 1-criterion. At the SUSD2 score, the sensi-
tivity and specificity for each outcome under study was 
plotted, thus generating an ROC. The score closest to 
the point with both maximum sensitivity and specific-
ity (i.e. the point [0.0, 1.0] on the curve) was selected as 
the cut-off score. Tumors designated as low expression 
of SUSD2 were those with the scores below or equal to 
the cut off value, while tumors of high expression were 
those with scores above the value. For the need of ROC 
curve analysis, the clinicopathologic characteristics were 
dichotomized: T status (T1–T2 versus T3–T4), N status 
(N0 versus N1), clinical stage (I–II versus III–IV), histo-
logical grade (G1–G2 versus G3).
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Cell culture
The human HCC cell lines, HepG2 and SMMC7721 
were obtained from laboratory preservation. These 
cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM High Glucose, Hyclone, USA) supple-
mented with 10  % heat-inactivated fetal bovine serum 
(Gibco, USA), penicillin (100  units/ml) and strepto-
mycin (100  μg/ml) at 37  °C in a humidified 5  % CO2 
atmosphere.
Vector construction and cell transfection
For SUSD2 overexpression, the open reading frame of 
SUSD2 was cloned into the multiple cloning site of the 
pcDNA3.1 between Hind III–EcoR I restriction sites and 
the empty pcDNA3.1 vector was used as control. psi-
mH1-SUSD2 containing a shRNA sequence (5′-GAAC 
GAGACGCGTTGGCAATA-3′) against SUSD2 was 
purchased from Guangzhou FulenGen. shRNA-scram-
ble (5′-GCTTCGCGCCGTAGTCTTA-3′) was used as 
control. The plasmid transfection was optimized using 
Lipofectamine 2000 according to the manufacturer’s 
instructions. Briefly, lipofectamine and plasmid were 
diluted separately in serum-free Opti-MEM (Gibco) and 
incubated at room temperature for 5  min. Afterward, 
the two solutions were gently mixed and incubated for 
20  min. Finally, the mixture was added to plated cells, 
and after 2 days, the cells were analyzed using the follow-
ing assays.
Cell proliferation assays
To determine the impact of SUSD2 on cell prolifera-
tion, HepG2 cells transfected with pcDNA3.1-SUSD2 or 
empty pcDNA3.1 vector, SMMC7721 cells transfected 
with psi-mH1-SUSD2 or shRNA-scramble were seeded 
onto 96-well plate (Corning inc, Corning NY) at a den-
sity of 1 ×  104 cells per well. Then at time points of 0, 
12, 24, 36, 48 h, the cell viability rate was assessed using 
cell counting kit-8 (KeyGEN BioTECH, China). 10  ul 
CCK-8 solution was added to each well and incubated for 
another 1 h and a microplate reader was used to meas-
ure the absorbance of each well at 450 nm. All the experi-
ments were independently repeated three times.
Analysis of cell apoptosis
The transfected HCC cell lines undergoing apopto-
sis were distinguished from live and necrotic cells by 
using Annexin-V and Propidium iodide (PI) staining 
Kit (KeyGEN BioTECH, China). Briefly, the concentra-
tion of transfected HCC cells was set to approximately 
1 × 105 cells/mL and were incubated with annexin-V/PI 
for 15  min at room temperature. Cells were then ana-
lyzed by means of flow cytometry using a two-color 
fluorescence-activated cell sorting (FACS) analysis (Beck-
man Coulter, cytomics FC 500, CA).
Wound–healing Assay
The ability of migration of HCC cells were analyzed by 
wound-healing assays. After 48 h of transfection, 5 × 105 
transfected cells were seeded on 6-well plates with 10 % 
FBS. Then the cells were grown to 80  % confluence, 
wounds were created by scraping the cells with a 100-μl 
pipette tip. After washed with PBS three times, cells were 
cultured by serum-free medium during the process. The 
microscope was used to photograph the migrated dis-
tance of cells after 48 h.
Invasion assays
For invasion assays, a total of 8  ×  104 various cells in 
100  μl serum-free DMEM medium were seeded in 
a Matrigelcoated chamber (8  μm pore size; BD Bio-
sciences) and the lower chamber was immediately filled 
with 500 μl of DMEM medium with 10 % FBS as a che-
moattractant. After 24 h of incubation in a humidifiedat-
mosphere containing 5 % CO2 at 37 °C, the non-invading 
cells are removed from the upper chamber by a cotton 
swab and the membranes were then fixed with methanol 
and stained by 0.1 % crystal violet.
Statistical analysis
Statistical analysis was performed by using the SPSS sta-
tistical software package (standard version 13.0; SPSS, 
Chicago, IL, USA). Receiver–operator curve (ROC) 
analysis was performed to determine the cut-off scores 
for high expression of SUSD2. The relationship between 
SUSD2 protein expression and HCC patients’ clinico-
pathologic features was estimated by χ2-test. Differences 
between groups were analyzed using Student’s t test and 
the P value less than 0.05 was considered to be statisti-
cally significant.
Results
The expression level of SUSD2 mRNA and protein in paired 
HCC and adjacent normal liver tissues
To assess the protein and mRNA expression of SUSD2 
in HCC, western blotting and qRT-PCR was employed 
to measure the expression status in 8 pairs of fresh HCC 
tissue and adjacent normal prostate tissues. Western 
blotting showed that 7/8 HCCs displayed reduced level 
of SUSD2 compared with the adjacent normal liver tis-
sues (Fig. 1a). Similar results for mRNA expression were 
observed using qRT-PCR. The results showed that in 7of 
the 8 sample pairs, mRNA fold changes (the 2−△△Ct val-
ues) were less than 1 between HCC and adjacent normal 
liver tissue which indicated the SUSD2 mRNA expression 
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was downregulated in HCC tissues compared to the adja-
cent normal liver tissues (Fig. 1b). The mean fold change 
is 0.385 and paired t test showed that difference between 
the two groups was statistically significant (Fig.  1c) 
(P < 0.05).
IHC Analysis of SUSD2 expression and selection of cut‑off 
score for high expression of SUSD2 in HCC tissues
We further examined the expression and subcellular 
localization of the SUSD2 protein by IHC in a TMA, 
which including 180 cases of HCC and 16 cases of nor-
mal liver tissue. For SUSD2 IHC staining in HCC tissues 
and normal liver tissues, SUSD2 is primarily expressed in 
the cytoplasm within tumor cells (Fig.  2). The ROC for 
each clinicopathological feature (Fig.  3) show the point 
on the curve closest to (0.0, 1.0), which maximizes both 
sensitivity and specificity for the outcome. Tumors with 
scores above the obtained cut-off value were considered 
as highly expressed SUSD2, leading to the greatest num-
ber of tumors correctly classified as having or not hav-
ing the clinical outcome. The corresponding area under 
the curve (AUC) (95  % confidence interval [CI]) are 
listed in Table  1. In our current study, optimal cut-off 
score for SUSD2 was determined by the ROC curve for 
clinical stage which showed the shortest distance to the 
point (0.0, 1.0) and could maximize both the sensitivity 
and specificity. According to ROC analysis, expression 
percentage for SUSD2 above the critical value 52.5 % was 
defined as positivity. The positive expression of SUSD2 
was detected in 16⁄16 (100 %) of non-cancerous adjacent 
tissues. However, the high expression of SUSD2 was only 
detected in 37.8 % (68 of 180) HCC cases and the remain-
ing 62.2 % (112 of 180) were scored as having no or low 
SUSD2 expression.
Correlations between SUSD2 expression 
and clinicopathological parameters of HCC patients
The relationship between SUSD2 scores with respect 
to patient clinicopathological features was detailed 
in Table  2. The results demonstrated that low expres-
sion of SUSD2 was positively correlated with tumor 
advanced clinical stage (χ2 = 30.244, P < 0.05), pT status 
(χ2 = 33.175, P < 0.05), pN status (χ2 = 4.785, P < 0.05) 
and histological grade (χ2 =  5.198, P < 0.05), pM status 
(χ2  =  4.620, P  <  0.05). However, there was no statisti-
cally significant correlations between SUSD2 expression 
and other clinicopathologic features, such as patient 
gender (χ2 = 1.093, P > 0.05), age at diagnosis (χ2 = 0.31, 
P > 0.05).
Effects of SUSD2 on the proliferation of HCC Cells in vitro
To investigate the function of SUSD2 in the tumorigene-
sis of HCC, we changed the expression level of SUSD2 in 
HepG2 cells and SMMC7721 cells. The HepG2 cells dis-
played a low level of SUSD2 and SMMC7721 displayed 
a high level of SUSD2. Then, we up-regulated SUSD2 in 
HepG2 cells by the transient transfection of pcDNA3.1-
SUSD2 and down-regulated expression of SUSD2 in 
Fig. 1 Expression of SUSD2 in HCC tissues and paired normal liver tissues detected by western blotting and qRT‑PCR. a Low expression of SUSD2 
protein was detected by Western blotting in HCC cases (7/8) compared with paired normal liver tissues. β‑actin was used as internal control. T, HCC 
tissues; N, paired normal liver tissues. b Fold changes (2−△△Ct values) by qRT‑PCR showed a reduced expression of SUSD2 mRNA in the majority of 
HCC cases (7/8) compared with paired normal liver tissues. Expression levels were normalized for β‑actin. c Significant differences of SUSD2 mRNA 
expression between the HCC and paired normal liver tissues (P < 0.05)
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Fig. 2 The expression of SUSD2 protein in HCC tissues and normal liver tissues by IHC on the TMA. a Weak staining of SUSD2 was detected in a HCC 
tissue. b Moderate staining of SUSD2 was detected in a HCC tissue, in which more than 70 % of HCC cells stain positively for SUSD2 protein in the 
cytoplasm. c Strong staining of SUSD2 was detected in a HCC case, in which more than 90 % HCC cells showed positive staining of SUSD2 protein 
in the cytoplasm. d Strong staining of SUSD2 was detected in a normal liver tissue, in which about 100 % cells showed positive staining of SUSD2 
protein in the cytoplasm. e–h demonstrate the higher magnification (400×) from the area of black square in (a–d), respectively
Fig. 3 Selection of the optimum cut‑off score for positive expression of SUSD2 by receiver operating characteristic (ROC) analysis. Various ROC 
curves were plotted by sensitivity and specificity for each clinical characteristic,including: age (a), sex (b), histological grade (c), clinical stage (d), pT 
status (e), pN status (f), pN status (g)
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SMMC7721 cells by the transient transfection of psi-
mH1-SUSD2 (Fig.  4a, b). To explore whether SUSD2 
affects the growth of HCC cells, we conducted cell pro-
liferation by using CCK-8 assays. The results showed 
that down-regulation of SUSD2 significantly increased 
the growth of SMMC7721/KD cells in comparison with 
control cells (Fig.  4c) (P  <  0.05). On the contrary with 
the down-regulation results, the up-regulation of SUSD2 
significantly inhibited the HepG2/SUSD2 proliferation 
in comparison with control cells (Fig.  4d) (P  <  0.05). 
Taken together, the results indicate that SUSD2 func-
tions as a tumor suppressor and play a role in cellular 
proliferation.
Effects of SUSD2 on the cell apoptosis of HCC Cells
To examine whether SUSD2 expression influences the cell 
apoptosis of HCC cells, we conducted cell apoptosis using 
Annexin V-FITC/PI double staining by flow cytometry. 
Annexin V-FITC+/PI- signifies the presence of apoptotic 
cells at an early stage and Annexin V-FITC+/PI+ signifies 
the late apoptotic cells. The results indicate that SUSD2 
knock down significantly reduced cell apoptosis com-
pared with cells treated with scramble shRNA (Fig. 5a, b) 
(P < 0.05). Furthermore, we carried out a similar experi-
ment and found that HCC cells with SUSD2 overexpres-
sion promoted cell apoptosis (Fig. 5c, d) (P < 0.05).
Effects of SUSD2 on the HCC cell migration and invasion
We next conducted wound-healing assay and transwell 
assays to examine whether SUSD2 expression influence 
the ability of HCC cells on cell migration and invasion.
The results showed that SUSD2 knock down significantly 
increase cellular migration of SMMC7721 cells (Fig. 6a). 
And SUSD2 up-regulation significantly decreased 
Table 1 Area under  the receiver operating characteristic 
curve for each clinicopathological features
AUC area under the curve, CI confidence interval
Feature AUC (95 % CI) P value
Age 0.540 (0.458–0.622) 0.338
Sex 0.524 (0.420–0.627) 0.636
Histological grade 0.704 (0.621–0.788) 0.000
Clinical Stage 0.769 (0.693–0.844) 0.000
pT status 0.758 (0.682–0.834) 0.000
pN status 0.721 (0.626–0.816) 0.001
pM status 0.619 (0.511–0.726) 0.039
Table 2 Relationship between SUSD2 expression and clin-
icopathological characteristics of HCC patients
a  Median age
b  P value are from Chi square test
Character‑
istics







Ages (years) 0.31 0.861
 ≤42a 45 27 (60.0) 18 (40.0)
 >42 135 79 (58.5) 56 (41.5)
Sex 1.093 0.296
 Female 45 29 (64.4) 16 (35.6)
 Male 135 75 (55.6) 60 (44.4)
Histological grade 5.198 0.023
 G1–G2 154 88 (57.1) 66 (42.9)
 G3 26 21 (80.8) 5 (19.2)
Clinical stage 30.244 0.000
 I–II 66 23 (34.8) 43 (65.2)
 III–IV 114 87 (76.3) 27 (23.7)
pT status 33.175 0.000
 T1–T2 76 24 (31.6) 52 (68.4)
 T3 104 78 (75) 26 (25)
pN status 4.785 0.029
 N0 160 63 (39.4) 97 (60.6)
 N1 20 13 (65) 7 (35)
pM status 4.620 0.032
 M0 164 67 (40.9) 97 (59.1)
 M1 16 11 (68.7) 5 (31.3)
Fig. 4 Alternations of SUSD2 expression modulated the growth of 
HCC cells in vitro. a Western blotting revealed that psi‑mH1‑SUSD2 
transduction down‑regulated SUSD2 in SMMC‑7721 cells at the 
protein level. b Western blotting revealed that pcDNA3.1‑SUSD2 
transduction up‑regulated SUSD2 in HepG2 cells at the protein level. 
c Growth curves showed that down‑regulation of SUSD2 promoted 
the growth of SMMC‑7721 cells by CCK8 assay in vitro. d Growth 
curves showed that upregulation of SUSD2 inhibited the growth of 
HepG2 cells by CCK8 assay in vitro
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cellular migration of HepG2 cells (Fig. 6b). Next, we car-
ried out an experiment to compare the ability of SUSD2 
on invasion. As shown in Fig. 7, SUSD2 down-regulation 
significantly increased invasion of SMMC7721 cells 
(P < 0.05).
Discussion
As is apparent with most disease processes, HCC is more 
effectively treated when it is diagnosed at an early stage. 
Unfortunately, the main serum tumor markers includ-
ing alpha-fetoprotein (AFP), lens culinaris agglutinin-
reactive AFP (AFP-L3), des-gamma carboxyprothrombin 
(DCP) and glypican-3 (GPC3) [16], failed to reach the 
optimal results when tested in the surveillance and early 
detection [17]. Despite these advances in molecular diag-
nosis of HCC, Nam SW and his colleagues proposed a 
3-gene signature, including GPC3, LYVE1 and survivin as 
an accurate molecular tool (>80 % accuracy) to discrimi-
nate dysplastic nodules and small HCC <2  cm in size, 
but restricted to HCV-related HCC [18]. Taken together, 
there is still an urgent need for us to identify novel bio-
markers which have important functions during HCC 
progression and that may help us find better diagnostic 
markers or therapeutic targets.
Although recent studies have focused on the relation-
ship between SUSD2 expression and multiple types of 
human cancer, such as breast, colon [13, 14], the expres-
sion pattern of SUSD2 protein and its biologic function 
has not been revealed in HCC. In the present study, we 
reported for the first time the SUSD2 expression levels of 
both the mRNA and protein were markedly reduced in 
the majority of HCC tissues, when compared with their 
paired adjacent normal liver tissues. Next, the expres-
sion of the SUSD2 protein was examined by IHC, using 
a TMA containing 180 HCC samples and 16 non-malig-
nant liver tissues. IHC results demonstrated that SUSD2 
high expression was observed in 100 % of non-malignant 
liver tissues when compared to that in the 37.8  % HCC 
tissues, suggesting that down-regulated of SUSD2 may 
provide a selective advantage in the HCC tumorigenic 
development and progression. Furthermore, in order to 
evaluate the association of SUSD2 expression with HCC 
patients’ clinicopathologic features, ROC analysis was 
carried out for each of the clinicopathological parame-
ters, including histological grade, clinical stage, pT stage, 
pN stage, pM stage. The analysis results showed signifi-
cant positive correlation between HCC and clinicopatho-
logical parameters we focused on, such as histological 
Fig. 5 The influence of SUSD2 on apoptosis of HCC cells.Annexin‑V/PI flow cytometric analysis of apoptosis in HCC cells. a, b Downregulation of 
SUSD2 could significantly inhibit apoptosis of SMMC‑7721cells compared with the control cells (P < 0.05); c, d Transfection with pcDNA3.1‑SUSD2 
significantly promoted apoptosis of HepG2 cells compared with the control cells (P < 0.05)
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Fig. 6 Ectopic expression of SUSD2 are responsible to migration in HCC cells. Migratory capabilities were analyzed by wound‑healing assay in 
HCC cells. a Downregulation of SUSD2 could have more migratory capabilities of SMMC‑7721 cells than their control groups. b Transfection with 
pcDNA3.1‑SUSD2 could inhibit migratory capabilities of HepG2 cells compared with the control groups
Fig. 7 The function of SUSD2 on invasion was assessed by transwell assay. a, b Downregulation of SUSD2 increased the invasive potential of 
SMMC‑7721 cells compared with the control groups (P < 0.05). c, d Overexpression of SUSD2 decreased the invasive potential of HepG2 cells com‑
pared with the control groups (P < 0.05)
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grade (χ2 = 5.198, P = 0.007), clinical stage (χ2 = 30.244, 
P =  0.000), pT status (χ2 =  33.175, P =  0.000) and pN 
status (χ2  =  4.785, P  =  0.000), pM status (χ2  =  4.620, 
P  =  0.032). These data provided evidence that the 
decreased expression of SUSD2 may play an important 
role in tumorigenic process of HCC and may serve as a 
potential marker for the diagnosis of HCC.
To investigate the possibility that SUSD2 could sup-
press the tumorigenesis of HCC, we altered the expres-
sion of SUSD2 in HCC cell lines by up-regulation and 
down-regulation. As expected, up-regulation of SUSD2 
in HepG2 cells significantly inhibited the cell prolifera-
tion and promoted cell apoptosis compared with those 
of the cells transfected with empty vectors. Consist-
ently, down-regulation of SUSD2 in SMMC7721 cells 
enhanced the cell proliferation and decreased cell apop-
tosis compared with those of the cells transfected with 
empty vectors. Taken together, these results suggested 
that SUSD2 played as a tumor suppressor and thus inhib-
ited the growth of HCC tumors in vitro. Furthermore,in 
our study, we proved that up-regulation of SUSD2 sig-
nificantly decreased the migration and ability of HepG2 
cells to invade through Matrigel, a basement membrane 
that used to imitate the metastatic potential of cancer 
cells. Metastasis is the main cause of cancer recurrence 
and tumor-related death [19, 20], the absence of SUSD2 
in HCC may represent advanced disease and poor prog-
nosis for the patient.
The major finding from this study provide evidence 
that SUSD2 expressed in HCC were less than that in the 
adjacent liver normal tissues. A low level of SUSD2 is 
associated with clinicopathologic parameters and repre-
sents a more aggressive status of HCC. We have proven 
that up-regulation of SUSD2 may reverse tumor forma-
tion, making it a potentially effective biomaker,but the 
mechanisms of SUSD2 in HCC carcinogenesis and the 
prognostic value of SUSD2 in HCC patients are needed 
in further studies.
Conclusion
In conclusion, SUSD2 was down-regulated in HCC tis-
sues and related to histological grade, clinical stage, 
TNM stage. We also provided evidence demonstrating 
SUSD2 affected HCC cells proliferation, invasion, migra-
tion, apoptosis. SUSD2 may be a potential marker for the 
diagnosis of HCC.
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